A citation-based method for searching scientific literature

James D Berry, Robert Miller, Dan H Moore, Merit E Cudkowicz, Leonard H van den Berg, Douglas A Kerr, Yingwen Dong, Evan W Ingersoll, Donald Archibald. Amyotroph Lateral Scler Frontotemporal Degener 2013
Times Cited: 66







List of co-cited articles
399 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III).
J M Cedarbaum, N Stambler, E Malta, C Fuller, D Hilt, B Thurmond, A Nakanishi. J Neurol Sci 1999
36

Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial.
Merit E Cudkowicz, Leonard H van den Berg, Jeremy M Shefner, Hiroshi Mitsumoto, Jesus S Mora, Albert Ludolph, Orla Hardiman, Michael E Bozik, Evan W Ingersoll, Donald Archibald,[...]. Lancet Neurol 2013
163
36

Combining mortality and longitudinal measures in clinical trials.
D M Finkelstein, D A Schoenfeld. Stat Med 1999
121
24

El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis.
B R Brooks, R G Miller, M Swash, T L Munsat. Amyotroph Lateral Scler Other Motor Neuron Disord 2000
22



Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS.
F Kimura, C Fujimura, S Ishida, H Nakajima, D Furutama, H Uehara, K Shinoda, M Sugino, T Hanafusa. Neurology 2006
310
18

Comparing methods to combine functional loss and mortality in clinical trials for amyotrophic lateral sclerosis.
Ruben Pa van Eijk, Marinus Jc Eijkemans, Dimitris Rizopoulos, Leonard H van den Berg, Stavros Nikolakopoulos. Clin Epidemiol 2018
22
54

Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model.
Henk-Jan Westeneng, Thomas P A Debray, Anne E Visser, Ruben P A van Eijk, James P K Rooney, Andrea Calvo, Sarah Martin, Christopher J McDermott, Alexander G Thompson, Susana Pinto,[...]. Lancet Neurol 2018
189
16

The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis.
Merit Cudkowicz, Michael E Bozik, Evan W Ingersoll, Robert Miller, Hiroshi Mitsumoto, Jeremy Shefner, Dan H Moore, David Schoenfeld, James L Mather, Donald Archibald,[...]. Nat Med 2011
130
15

Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial.
K E Morrison, S Dhariwal, R Hornabrook, L Savage, D J Burn, T K Khoo, J Kelly, C L Murphy, A Al-Chalabi, A Dougherty,[...]. Lancet Neurol 2013
90
15



Progression in ALS is not linear but is curvilinear.
Paul H Gordon, Bin Cheng, Francois Salachas, Pierre-Francois Pradat, Gaelle Bruneteau, Philippe Corcia, Lucette Lacomblez, Vincent Meininger. J Neurol 2010
90
13

Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients.
Koji Abe, Yasuto Itoyama, Gen Sobue, Shoji Tsuji, Masashi Aoki, Manabu Doyu, Chikuma Hamada, Kazuoki Kondo, Takatomo Yoneoka, Makoto Akimoto,[...]. Amyotroph Lateral Scler Frontotemporal Degener 2014
176
13

Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
Robert G Miller, J D Mitchell, Dan H Moore. Cochrane Database Syst Rev 2012
441
12


Evidence of multidimensionality in the ALSFRS-R Scale: a critical appraisal on its measurement properties using Rasch analysis.
Franco Franchignoni, Gabriele Mora, Andrea Giordano, Paolo Volanti, Adriano Chiò. J Neurol Neurosurg Psychiatry 2013
94
12

The PRO-ACT database: design, initial analyses, and predictive features.
Nazem Atassi, James Berry, Amy Shui, Neta Zach, Alexander Sherman, Ervin Sinani, Jason Walker, Igor Katsovskiy, David Schoenfeld, Merit Cudkowicz,[...]. Neurology 2014
147
12

Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials.
Leonard H van den Berg, Eric Sorenson, Gary Gronseth, Eric A Macklin, Jinsy Andrews, Robert H Baloh, Michael Benatar, James D Berry, Adriano Chio, Philippe Corcia,[...]. Neurology 2019
72
12

Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial.
Paul H Gordon, Dan H Moore, Robert G Miller, Julaine M Florence, Joseph L Verheijde, Carolyn Doorish, Joan F Hilton, G Mark Spitalny, Robert B MacArthur, Hiroshi Mitsumoto,[...]. Lancet Neurol 2007
478
10

EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)--revised report of an EFNS task force.
Peter M Andersen, Sharon Abrahams, Gian D Borasio, Mamede de Carvalho, Adriano Chio, Philip Van Damme, Orla Hardiman, Katja Kollewe, Karen E Morrison, Susanne Petri,[...]. Eur J Neurol 2012
603
10

An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study.
Timothy M Miller, Alan Pestronk, William David, Jeffrey Rothstein, Ericka Simpson, Stanley H Appel, Patricia L Andres, Katy Mahoney, Peggy Allred, Katie Alexander,[...]. Lancet Neurol 2013
416
10

A proposed staging system for amyotrophic lateral sclerosis.
Jose C Roche, Ricardo Rojas-Garcia, Kirsten M Scott, William Scotton, Catherine E Ellis, Rachel Burman, Lokesh Wijesekera, Martin R Turner, P Nigel Leigh, Christopher E Shaw,[...]. Brain 2012
200
10

Electrical impedance myography as a biomarker to assess ALS progression.
Seward B Rutkove, James B Caress, Michael S Cartwright, Ted M Burns, Judy Warder, William S David, Namita Goyal, Nicholas J Maragakis, Lora Clawson, Michael Benatar,[...]. Amyotroph Lateral Scler 2012
109
10

A further Rasch study confirms that ALSFRS-R does not conform to fundamental measurement requirements.
Franco Franchignoni, Jessica Mandrioli, Andrea Giordano, Salvatore Ferro. Amyotroph Lateral Scler Frontotemporal Degener 2015
38
18

Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved?
Hiroshi Mitsumoto, Benjamin R Brooks, Vincenzo Silani. Lancet Neurol 2014
183
10

Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
Swati P Aggarwal, Lorne Zinman, Elizabeth Simpson, Jane McKinley, Katherine E Jackson, Hanika Pinto, Petra Kaufman, Robin A Conwit, David Schoenfeld, Jeremy Shefner,[...]. Lancet Neurol 2010
136
9

Toward more efficient clinical trials for amyotrophic lateral sclerosis.
Merit E Cudkowicz, Jon Katz, Dan H Moore, Gilmore O'Neill, Jonathan D Glass, Hiroshi Mitsumoto, Stanley Appel, Bernard Ravina, Karl Kieburtz, Ira Shoulson,[...]. Amyotroph Lateral Scler 2010
61
9

Multipoint incremental motor unit number estimation as an outcome measure in ALS.
J M Shefner, M L Watson, L Simionescu, J B Caress, T M Burns, N J Maragakis, M Benatar, W S David, K R Sharma, S B Rutkove. Neurology 2011
100
9

The ALSFRSr predicts survival time in an ALS clinic population.
P Kaufmann, G Levy, J L P Thompson, M L Delbene, V Battista, P H Gordon, L P Rowland, B Levin, H Mitsumoto. Neurology 2005
162
9

Quantifying disease progression in amyotrophic lateral sclerosis.
Neil G Simon, Martin R Turner, Steve Vucic, Ammar Al-Chalabi, Jeremy Shefner, Catherine Lomen-Hoerth, Matthew C Kiernan. Ann Neurol 2014
109
9

Addressing heterogeneity in amyotrophic lateral sclerosis CLINICAL TRIALS.
Namita A Goyal, James D Berry, Anthony Windebank, Nathan P Staff, Nicholas J Maragakis, Leonard H van den Berg, Angela Genge, Robert Miller, Robert H Baloh, Ralph Kern,[...]. Muscle Nerve 2020
27
22

Controversies and priorities in amyotrophic lateral sclerosis.
Martin R Turner, Orla Hardiman, Michael Benatar, Benjamin R Brooks, Adriano Chio, Mamede de Carvalho, Paul G Ince, Cindy Lin, Robert G Miller, Hiroshi Mitsumoto,[...]. Lancet Neurol 2013
353
7


Amyotrophic lateral sclerosis.
Matthew C Kiernan, Steve Vucic, Benjamin C Cheah, Martin R Turner, Andrew Eisen, Orla Hardiman, James R Burrell, Margaret C Zoing. Lancet 2011
7

A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis.
M E Cudkowicz, J M Shefner, D A Schoenfeld, R H Brown, H Johnson, M Qureshi, M Jacobs, J D Rothstein, S H Appel, R M Pascuzzi,[...]. Neurology 2003
162
7

State of play in amyotrophic lateral sclerosis genetics.
Alan E Renton, Adriano Chiò, Bryan J Traynor. Nat Neurosci 2014
965
7

Biomarkers in amyotrophic lateral sclerosis.
Martin R Turner, Matthew C Kiernan, P Nigel Leigh, Kevin Talbot. Lancet Neurol 2009
313
7

Prognostic factors in ALS: A critical review.
Adriano Chiò, Giancarlo Logroscino, Orla Hardiman, Robert Swingler, Douglas Mitchell, Ettore Beghi, Bryan G Traynor. Amyotroph Lateral Scler 2009
571
7

Axonal damage markers in cerebrospinal fluid are increased in ALS.
J Brettschneider, A Petzold, S D Süssmuth, A C Ludolph, H Tumani. Neurology 2006
185
7

Dexpramipexole effects on functional decline and survival in subjects with amyotrophic lateral sclerosis in a Phase II study: subgroup analysis of demographic and clinical characteristics.
Stacy A Rudnicki, James D Berry, Evan Ingersoll, Don Archibald, Merit E Cudkowicz, Douglas A Kerr, Yingwen Dong. Amyotroph Lateral Scler Frontotemporal Degener 2013
24
20

Functional outcome measures as clinical trial endpoints in ALS.
B J Traynor, H Zhang, J M Shefner, D Schoenfeld, M E Cudkowicz. Neurology 2004
97
7

Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial.
Merit E Cudkowicz, Sarah Titus, Marianne Kearney, Hong Yu, Alexander Sherman, David Schoenfeld, Douglas Hayden, Amy Shui, Benjamin Brooks, Robin Conwit,[...]. Lancet Neurol 2014
139
7

Defining survival as an outcome measure in amyotrophic lateral sclerosis.
Paul H Gordon, Philippe Corcia, Lucette Lacomblez, Ksenia Pochigaeva, Jean-Louis Abitbol, Merit Cudkowicz, P Nigel Leigh, Vincent Meininger. Arch Neurol 2009
29
17

How can we improve clinical trials in amyotrophic lateral sclerosis?
Paul H Gordon, Vincent Meininger. Nat Rev Neurol 2011
40
12

Clinical significance in the change of decline in ALSFRS-R.
Carmen Castrillo-Viguera, Daniela L Grasso, Elizabeth Simpson, Jeremy Shefner, Merit E Cudkowicz. Amyotroph Lateral Scler 2010
53
9

What does the ALSFRS-R really measure? A longitudinal and survival analysis of functional dimension subscores in amyotrophic lateral sclerosis.
James Rooney, Tom Burke, Alice Vajda, Mark Heverin, Orla Hardiman. J Neurol Neurosurg Psychiatry 2017
68
7

Amyotrophic lateral sclerosis.
Michael A van Es, Orla Hardiman, Adriano Chio, Ammar Al-Chalabi, R Jeroen Pasterkamp, Jan H Veldink, Leonard H van den Berg. Lancet 2017
506
7

Amyotrophic Lateral Sclerosis.
Robert H Brown, Ammar Al-Chalabi. N Engl J Med 2017
736
7


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.